GENE ONLINE|News &
Dr. Reddy’s Laboratories Gains Health Canada Approval for Generic Semaglutide Injection in 2 mg and 4 mg Pens
Dr. Reddy’s Laboratories secured approval from Health Canada for its generic version of Semaglutide injection. The authorization extends to 2 mg and 4 mg pen presentations of the drug within the Canadian market.
The approval by Health Canada allows Dr. Reddy’s to manufacture and distribute its generic Semaglutide injection in 2 mg and 4 mg pen formats. This development provides an alternative treatment option for patients requiring Semaglutide.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: April 29, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Digitalis Glycosides Studied for Heart Failure Treatment at ESC Heart Failure 2026 Congress
2026-05-10
Digoxin Lowers Death Risk and Heart Failure in Rheumatic Heart Disease Patients, Study Finds
2026-05-10
New Test Detects Biomarkers for Frontotemporal Lobar Degeneration, a Rare Dementia Affecting Over 57 Million Globally
2026-05-10
